New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists

References

• AndersonJAkkinaRComplete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infectionGene Ther20071412879717597795
   PubMed Web of Science ®Google Scholar
• BabaMNishimuraOKanzakiNA small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activityProc Natl Acad Sci USA199996569870310318947
   PubMed Web of Science ®Google Scholar
• BabaMTakashimaKMiyakeHTAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humansAntimicrob Agents Chemother20054945849116251299
   PubMed Web of Science ®Google Scholar
• BartlettJADeMasiRQuinnJOverview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1-1-1 infected adultsAIDS20011513697711504958
   PubMed Web of Science ®Google Scholar
• BlanpainCMigeotteILeeBCCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonistBlood199994189990510477718
   PubMed Web of Science ®Google Scholar
• BrummeZLGoodrichJMayerHBMolecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naïve individualsJ Infect Dis20051924667415995960
   PubMed Web of Science ®Google Scholar
• ChanDCFassDBergerJMCore structure of gp41 from the HIV envelope glycoproteinCell199789263739108481
   PubMed Web of Science ®Google Scholar
• ChanDCKimPSHIV entry and its inhibitionCell19989368149630213
   PubMed Web of Science ®Google Scholar
• CoakleyEPetropoulosCJWhitcombJMAssessing chemokine co-receptor usage in HIVCurr Opin Infect Dis20051891515647694
   PubMed Web of Science ®Google Scholar
• CocchiFDeVicoALGarzino-DemoAIdentification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cellsScience19952701811158525373
   PubMed Web of Science ®Google Scholar
• ConnorRISheridanKECeradiniDChange in coreceptor use correlates with disease progression in HIV-1 infected individualsJ Exp Med199718562189034141
   PubMed Web of Science ®Google Scholar
• CooperDGatellJRockstrohJResults from BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1integrase inhibitor, in patients with triple-class resistant virus2007Program and abstracts of the 14th Conference on Retroviruses and Opportunistic InfectionsLos Angeles, CA Abstract 105aLB
   Google Scholar
• CrabbCGlaxoSmithKline ends aplaviroc trialsAIDS20062064116514292
   PubMed Web of Science ®Google Scholar
• DaarESKeslerKLPetropoulosCJHemophilia Growth and Development Study. Baseline HIV type 1 coreceptor tropism predicts disease progressionClin Infect Dis200745643917683002
   PubMed Web of Science ®Google Scholar
• DalgleishAGBeverleyPCClaphamPRThe CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirusNature198431276376096719
   PubMed Web of Science ®Google Scholar
• DeanMCarringtonMWinklerCGenetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene: Hemophilia Growth and Development Study, Multi-center AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE StudyScience19962731856628791590
   PubMed Web of Science ®Google Scholar
• DeeksSGChallenges of developing R5 inhibitors in antiretroviral naive HIV-infected patientsLancet2006367711316517257
   PubMed Web of Science ®Google Scholar
• DorrPWestbyMDobbsSMaraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activityAntimicrob Agents Chemother20054947213216251317
   PubMed Web of Science ®Google Scholar
• DragicTLitwinVAllawayGPHIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5Nature1996381667738649512
   PubMed Web of Science ®Google Scholar
• DragicTTrkolaAThompsonDAA binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5Proc Natl Acad Sci USA20009756394410779565
   PubMed Web of Science ®Google Scholar
• EckertDMKimPSMechanisms of viral membrane fusion and its inhibitionAnnu Rev Biochem20017077781011395423
   PubMed Web of Science ®Google Scholar
• FätkenheuerGPozniakALJohnsonMAEfficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1Nat Med2005111170216205738
   PubMed Web of Science ®Google Scholar
• FischerederMLuckowBHocherBCC chemokine receptor 5 and renal-tranplant survivalLancet200135717586111403814
   PubMed Web of Science ®Google Scholar
• GalvaniAPSlatkinMEvaluating plague and smallpox as historical selective pressures for the CCR5-Δ32 HIV-resistance alleleProc Natl Acad Sci USA200310015276914645720
   PubMed Web of Science ®Google Scholar
• GlassWGMcDermottDHLimJKCCR5 deficiency increases risk of symptomatic West Nile virus infectionJ Exp Med2006203354016418398
   PubMed Web of Science ®Google Scholar
• GoetzMBLeducRKostmanJRPrediction of disease progression by HIV coreceptor tropism in persons with untreated chronic HIV infection2007Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, Ill Abstract H-1027
   Google Scholar
• GoodrichJMSaagMvan der RystE48-week safety and efficacy of maraviroc, a novel ccr5 antagonist, in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced patients infected with dual/mixed-tropic HIV-12007Program and abstracts of the 45th Annual Infectious Diseases Society of AmericaSan Diego, CA Abstract LB-2
   Google Scholar
• GreavesWLandovitzRFätkenheuerGLate Virologic breakthrough in treatment-naive patients on a regimen of combivir + vicriviroc2006Program and abstracts of the 13th Conference on Retroviruses and Opportunistic InfectionsDenver, CO Abstract 161LB
   Google Scholar
• GulickRSuZFlexnerCPhase II study of the safety and efficacy of vicriviroc in HIV-infected treatment-experienced subjects: ACTG 5211J Infect Dis2007a1963041217570119
   PubMed Web of Science ®Google Scholar
• GulickRSuZFlexnerCfor the ACTG 5211 TeamACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results2007bProgram and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and PreventionSydney, Australia Abstract TUAB102
   Google Scholar
• GulickRHaasDCollierATwo-year follow-up of treatment-experienced patients on vicriviroc (VCV)2007cProgram and abstracts of the 47th Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, IL Abstract H-1030
   Google Scholar
• GulickRMvan der RystELampirisHEfficacy and safety of once-daily (QD) compared with twice-daily (BID) maraviroc plus optimized background therapy (OBT) in treatment-experienced patients infected with CCR5-tropic-HIV-1: 24-week combined analysis of the MOTIVATE 1 and 2 studies2007dProgram and abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention Abstract WEPEB116LB
   Google Scholar
• GuoQHoHTDickerIBiochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactionsJ Virol200377105283612970437
   PubMed Web of Science ®Google Scholar
• HammerSMSaagMSSchechterMInternational AIDS Society-USA panel. Treatment for adult HIV-1 infection: 2006 recommendations of the International AIDS Society-USA panelJAMA20062968274316905788
   PubMed Web of Science ®Google Scholar
• HartleyOGaertnerHWilkenJMedicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitorsProc Natl Acad Sci USA200410116460515545608
   PubMed Web of Science ®Google Scholar
• HolmbergSDHamburgerEMMoormanACFactors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppressionClin Infect Dis200337702712942404
   PubMed Web of Science ®Google Scholar
• HuangYPaxtonWAWolinskySMThe role of a mutant CCR5 allele in HIV-1 transmission and disease progressionNat Med19962124038898752
   PubMed Web of Science ®Google Scholar
• JacobsonJMIsraelRJLowyITreatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542Antimicrob Agents Chemother200448423914742190
   PubMed Web of Science ®Google Scholar
• JacobsonJMThompsonMSaagMSAntiretroviral Activity and Pharmacodynamics of PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Individuals2007Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, IL Abstract H-716
   Google Scholar
• JiCZhangJDioszegiMCCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptorMol Pharmacol200772182817392523
   PubMed Web of Science ®Google Scholar
• JouvenotYPerezEUrnovFDTowards Gene Knock Out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs)2005Program and abstracts of the 45th Annual Interscience Conference on Antimicrobial Agents and ChemotherapyWashington, DC Abstract H-1084
   Google Scholar
• KadowJWangHGLinPFSmall-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug developmentCurr Opin Investig Drugs200677216
   PubMedGoogle Scholar
• KootMKeetIPVosAHPrognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDSAnn Intern Med199311868188096374
   PubMed Web of Science ®Google Scholar
• KuhmannSEPugachPKunstmanKJGenetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitorJ Virol2004782790807 Erratum in: J Virol, 2005 78:670614990699
   PubMed Web of Science ®Google Scholar
• KwongPDWyattRRobinsonJStructure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibodyNature1998393648599641677
   PubMed Web of Science ®Google Scholar
• LalezariJThompsonMKumarPAntiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adultsAIDS2005191443816135896
   PubMed Web of Science ®Google Scholar
• LalezariJLedermanMYadavalliGA phase 1, dose-escalation, placebo-controlled study of a fully human monoclonal antibody (CCR5mAb004) against CCR5 in patients with CCR5-tropic HIV-1 infection2006Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and ChemotherapySan Francisco, CA Abstract H-1668
   Google Scholar
• LalezariJGoodrichJDeJesusEMOTIVATE 1. USA and Canada. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of phase 2b/3 studies2007Program and abstracts of the 14th Conference on Retroviruses and Opportunistic InfectionsLos Angeles, CA Abstract 104bLB
   Google Scholar
• LapidotTMechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactionsAnn NY Acad Sci2001938839511458529
   PubMed Web of Science ®Google Scholar
• LiuRPaxtonWAChoeSHomozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infectionCell199686367778756719
   PubMed Web of Science ®Google Scholar
• LutherSACysterJGChemokines as regulators of T cell differentiationNat Immunol20012102711175801
   PubMed Web of Science ®Google Scholar
• MaedaKYoshimuraKShibayamaSNovel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5J Biol Chem20012763519420011454872
   PubMed Web of Science ®Google Scholar
• MaedaKNakataHKohYSpirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitroJ Virol20047886546215280474
   PubMed Web of Science ®Google Scholar
• ManiMKandavelouKDyFJDesign, engineering, and characterization of zinc finger nucleasesBiochem Biophys Res Commun20053354475716084494
   PubMed Web of Science ®Google Scholar
• MarkowitzMMohriHMehandruSInfection with multidrug resistant, dual-tropic HIV-1and rapid progression to AIDS: a case reportLancet20053651031815781098
   PubMed Web of Science ®Google Scholar
• MarozsanAJKuhmannSEMorganTGeneration and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)Virology20053381829915935415
   PubMed Web of Science ®Google Scholar
• MelbyTDespiritoMDemasiRHIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide responseJ Infect Dis20061942384616779731
   PubMed Web of Science ®Google Scholar
• MocroftAPhillipsANFriis-MollerNResponse to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA StudyAntivir Ther20021213012008784
   PubMed Web of Science ®Google Scholar
• MoriJMosleyMLewisMCharacterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 22007Program and abstracts of the 16th International HIV Drug Resistance WorkshopBarbados, West Indies Abstract 10
   Google Scholar
• MosleyMSmith-BurchnellCMoriJResistance to the CCR5 antagonist maraviroc is characterized by dose-response curves that display a reduction in maximal inhibition2006Program and abstracts of the 13th Conference on Retroviruses and Opportunistic InfectionsDenver, Colorado Abstract 598
   Google Scholar
• MoyleGJWildfireAMandaliaSEpidemiology and predictive factors for chemokine receptor use in HIV-1 infectionJ Infect Dis20051918667215717260
   PubMed Web of Science ®Google Scholar
• MoyleGJDeJesusEBoffitoMCXCR4 antagonism: proof of activity with AMD110702007Program and abstracts of the 14th Conference on Retroviruses and Opportunistic InfectionsLos Angeles, CA Abstract 511
   Google Scholar
• MurgaJDFrantiMPevearDCPotent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1Antimicrob Agents Chemother20065032899617005807
   PubMed Web of Science ®Google Scholar
• NakataHMaedaKMiyakawaTPotent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse modelJ Virol20057920879615681411
   PubMed Web of Science ®Google Scholar
• NelsonMFatkenheuerGKonourinaIMOTIVATE 2. Europe, Australia and USA. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of phase 2b/3 studies2007Program and abstracts of the 14th Conference on Retroviruses and Opportunistic InfectionsLos Angeles, CA Abstract 104aLB
   Google Scholar
• OldfieldVKeatingGMPloskerGEnfuvirtide: a review of its use in the management of HIV infectionDrugs20056511396015907147
   PubMed Web of Science ®Google Scholar
• OlsonWCRabutGENagashimaKADifferential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5J Virol199973541455510196311
   PubMed Web of Science ®Google Scholar
• OppermannMChemokine receptor CCR5: insights into structure, function, and regulationCell Signal20041612011015337520
   PubMed Web of Science ®Google Scholar
• PalellaFJJrDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV-1 Outpatient Study InvestigatorsN Engl J Med1998338853609516219
   PubMed Web of Science ®Google Scholar
• PastoreCNedellecRRamosAHuman immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutationsJ Virol200680750816378977
   PubMed Web of Science ®Google Scholar
• PhilpottSMHIV-1 coreceptor usage, transmission, and disease progressionCurr HIV Res200312172715043204
   PubMed Web of Science ®Google Scholar
• PrahaladSNegative association between the chemokine receptor CCR5-[Delta]32 polymorphism and rheumatoid arthritis: a meta-analysisGenes Immun20067264816541097
   PubMed Web of Science ®Google Scholar
• PugachPMarozsanAJKetasTJHIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entryVirology20073612122817166540
   PubMed Web of Science ®Google Scholar
• QinXFAnDSChenISInhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5Proc Natl Acad Sci USA2003100183812518064
   PubMed Web of Science ®Google Scholar
• ReynesJRouzierRKanouniT SCH C:Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1-infected subjects2002Program and abstracts of the 9th Conference on Retroviruses and Opportunistic InfectionsSeattle, WA Abstract 1
   Google Scholar
• RoschkeVClarkSBrancoLCharacterization of a panel of novel human monoclonal antibodies that specifically antagonize CCR5 and Block HIV-1 entry2004Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and ChemotherapyWashington, D.C. Abstract #2871
   Google Scholar
• RuffingNSullivanNSharmeenLCCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cellsCell Immunol199818916089790730
   PubMed Web of Science ®Google Scholar
• SaagMIvePHeeraJA multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: Week 48 results of the MERIT study2007Program and abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and PreventionSydney, Australia Abstract WESS104
   Google Scholar
• SabetiPCWalshESchaffnerSFThe case for selection at CCR5-Delta32PLoS Biol20053e37816248677
   PubMed Web of Science ®Google Scholar
• SamsonMLibertFDoranzBJResistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor geneNature199638272258751444
   PubMed Web of Science ®Google Scholar
• SchooleyRTMellorsJWNo cure yet for HIV-1-1, but therapeutic research presses onJ Infect Dis2007195770217299705
   PubMed Web of Science ®Google Scholar
• SchurmannDFätkenheuerGReynesJAntiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adultsAIDS2007211293917545705
   PubMed Web of Science ®Google Scholar
• ShetABerryLMohriHTracking the prevalence of transmitted antiretroviral drug-resistant HIV-1-1: a decade of experienceJ Acquir Immune Defic Syndr2006414394616652051
   PubMed Web of Science ®Google Scholar
• SignoretNHewlettLWavreSAgonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependentMol Biol Cell2005169021715591129
   PubMed Web of Science ®Google Scholar
• SimmonsGClaphamPRPicardLPotent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonistScience199727627699092481
   PubMed Web of Science ®Google Scholar
• Starr-SpiresLDCollmanRGHIV-1 entry and entry inhibitors as therapeutic agentsClin Lab Med20022268170112244592
   PubMed Web of Science ®Google Scholar
• SteigbigelRKumarPEronJResults from BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1integrase inhibitor, in patients with triple-class resistant virus2007Program and abstracts of the 14th Conference on Retroviruses and Opportunistic InfectionsLos Angeles, CA Abstract 105bLB
   Google Scholar
• StephensJCReichDEGoldsteinDBDating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypesAm J Hum Genet1998621507159585595
   PubMed Web of Science ®Google Scholar
• StrizkiJMXuSWagnerNESCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoProc Natl Acad Sci USA200198127182311606733
   PubMed Web of Science ®Google Scholar
• StrizkiJMTremblayCXuSDiscovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1Antimicrob Agents Chemother2005494911916304152
   PubMed Web of Science ®Google Scholar
• TakashimaKMiyakeHKanzakiNHighly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonistAntimicrob Agents Chemother20054934748216048963
   PubMed Web of Science ®Google Scholar
• ThioCLAstemborskiJBashirovaAGenetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistenceJ Virol200781441517079285
   PubMed Web of Science ®Google Scholar
• TsamisFGavrilovSKajumoFAnalysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entryJ Virol2003775201812692222
   PubMed Web of Science ®Google Scholar
• TsibrisAMNGulickRMSuZIn vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc: findings from ACTG A52112007Program and abstracts of the 16th International HIV Drug Resistance WorkshopBarbados, West Indies Abstract 13
   Google Scholar
• UnutmazDKewalRamaniVNLittmanDRG protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions an on the utility of animal modelsSemin Immunol199810225369653049
   PubMed Web of Science ®Google Scholar
• van der RystEWestbyMChanges in HIV-1 co-receptor tropism for patients participating in the maraviroc Motivate 1 and 2 clinical trials2007Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, IL Abstract H-715
   Google Scholar
• WalenskyRPPaltielADLosinaEThe survival benefits of AIDS treatment in the United StatesJ Infect Dis200619411916741877
   PubMed Web of Science ®Google Scholar
• WestbyMLewisMWhitcombJEmergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoirJ Virol20068049092016641282
   PubMed Web of Science ®Google Scholar
• WestbyMSmith-BurchnellCMoriJReduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entryJ Virol20078123597117182681
   PubMed Web of Science ®Google Scholar
• WilkinTJSuZKuritzkesDRHIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211J Infect Dis2007445915
   Google Scholar
• WongMMFishENChemokines: attractive mediators of the immune responseSemin Immunol20031551412495636
   PubMed Web of Science ®Google Scholar
• WoodAArmourDThe discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDSProg Med Chem2005432397115850827
   PubMedGoogle Scholar
• ZhaoJMaLWuYLChemokine receptor CCR5 functionally couples to inhibitory G proteins and undergoes desensitizationJ Cell Biochem19987136459736452
   PubMed Web of Science ®Google Scholar